On July 10, Genscript Biotech rose 5.38% in regular trading, trading at HK$13.92/share, with turnover of approximately HK$58.13 million.

On the news front, the CXO sector entered the mid-year earnings disclosure window, with the innovative drug value chain's profitability logic beginning to materialize in financial statements. Multiple brokerages highlighted that new order growth for the CXO industry has accelerated significantly, and as previously discounted orders are gradually absorbed, both revenue and profit inflection points for the sector have been confirmed. Policy catalysts also emerged, with the National Healthcare Security Administration indicating higher drug registration volumes this year, while a newly introduced pre-application mechanism is expected to shorten the timeline for innovative drug inclusion in medical insurance by approximately one year.

The broader Life Sciences Tools and Services sector saw broad-based gains, with peers including Wuxi AppTec up 4.97%, Pharmaron up 7.12%, Wuxi Biologics up 4.86%, and Insilico up 7.43%. Genscript Biotech, as a leading gene synthesis and life science platform company, stands to benefit from both the CXO recovery cycle and surging AI-driven drug discovery demand, which has been driving accelerated growth in its life science services segment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)